Sylvester Karl P, Patey Richard A, Milligan Peter, Rafferty Gerrard F, Broughton Simon, Rees David, Thein Swee Lay, Greenough Anne
Departments of Child Health, Health and Life Sciences, and Haematological Medicine, King's College London School of Medicine at Guy's, King's College, and St Thomas' Hospitals, London, United Kingdom.
J Pediatr. 2006 Jul;149(1):17-22. doi: 10.1016/j.jpeds.2005.12.059.
To test the hypothesis that children with sickle cell disease (SCD) who experienced an acute chest syndrome (ACS) hospitalization episode would have worse lung function than children with SCD without ACS episodes.
Forced expiratory volume in 1 second (FEV(1)); forced vital capacity (FVC); FEV(1)/FVC ratio; peak expiratory flow (PEF); forced expiratory flow at 25% (FEF(25)), 50% (FEF(50)), and 75% (FEF(75)) of FVC; airway resistance (Raw); and lung volumes were compared in 20 children with ACS and 20 aged-matched children without ACS (median age, 11 years; range, 6 to 16 years). Fourteen age-matched pairs were assessed before and after bronchodilator use.
The mean Raw (P = .03), TLC (P = .01), and RV (P = .003) were significantly higher in the group with ACS than in the group without ACS. There were no significant differences in the changes in lung function test results in response to bronchodilator administration between the 2 groups, but the children with ACS had a lower FEF(25) (P = .04) and FEF(75) (P = .03) pre-bronchodilator use and a lower mean FEV(1)/FVC ratio (P = .03) and FEF(75) (P = .03) post-bronchodilator use.
Children with SCD who experienced an ACS hospitalization episode had significant differences in lung function compared with those who did not experience ACS episodes. Our results are compatible with the hypothesis that ACS episodes predispose children to increased airway obstruction.
检验以下假设,即经历过急性胸综合征(ACS)住院发作的镰状细胞病(SCD)患儿的肺功能比未经历过ACS发作的SCD患儿更差。
对20名患有ACS的儿童和20名年龄匹配的未患ACS的儿童(中位年龄11岁;范围6至16岁)进行了比较,测量指标包括1秒用力呼气容积(FEV(1))、用力肺活量(FVC)、FEV(1)/FVC比值、呼气峰值流速(PEF)、FVC的25%(FEF(25))、50%(FEF(50))和75%(FEF(75))时的用力呼气流量、气道阻力(Raw)和肺容积。对14对年龄匹配的儿童在使用支气管扩张剂前后进行了评估。
ACS组的平均Raw(P = .03)、TLC(P = .01)和RV(P = .003)显著高于无ACS组。两组在使用支气管扩张剂后肺功能测试结果的变化上无显著差异,但患有ACS的儿童在使用支气管扩张剂前的FEF(25)(P = .04)和FEF(75)(P = .03)较低,在使用支气管扩张剂后的平均FEV(1)/FVC比值(P = .03)和FEF(75)(P = .03)较低。
经历过ACS住院发作的SCD患儿与未经历过ACS发作的患儿在肺功能方面存在显著差异。我们的结果与以下假设相符,即ACS发作使儿童更容易出现气道阻塞。